FCM
TVRD

Flinton Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Flinton Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-44
Closed -$19K – 875
2018
Q1 		$19K Sell
44
-130
-75% -$63.1K ﹤0.01% 839
2017
Q4 		$77K Sell
174
-104
-37% -$47.4K ﹤0.01% 790
2017
Q3 		$137K Sell
278
-34
-11% -$17K ﹤0.01% 689
2017
Q2 		$173K Sell
312
-104
-25% -$66K 0.01% 617
2017
Q1 		$276K Hold
416
– – 0.01% 445
2016
Q4 		$139K Buy
+416
New +$134K 0.01% 529

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Flinton Capital Management's TVRD Position: Q2 2018 in Review

Flinton Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 44 shares — an estimated $19K sold.

Flinton Capital Management first reported a position in TVRD in Q4 2016 and held it in 6 quarters. The position peaked at $276K in Q1 2017. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Flinton Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Flinton Capital Management sold 44 Tvardi Therapeutics shares in Q2 2018, an estimated $19K.
  • Flinton Capital Management first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 6 quarters.
  • Flinton Capital Management's Tvardi Therapeutics position peaked at $276K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Flinton Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.